Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022;43(39):3925–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Afshar M, Thanassoulis G. Lipoprotein(a): new insights from modern genomics. Curr Opin Lipidol. 2017;28(2):170–6.

Article  CAS  PubMed  Google Scholar 

van Zuydam NR, Stiby A, Abdalla M, Austin E, Dahlström EH, McLachlan S, et al. Genome-wide Association study of Peripheral Artery Disease. Circ Genom Precis Med. 2021;14(5):e002862.

Article  PubMed  PubMed Central  Google Scholar 

Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. 2019;74(1):54–66.

Article  CAS  PubMed  Google Scholar 

Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of Heart failure in the General Population. JACC Heart Fail. 2016;4(1):78–87.

Article  PubMed  Google Scholar 

Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (justification for the Use of statins in Prevention: an intervention trial evaluating Rosuvastatin). Circulation. 2014;129(6):635–42.

Article  CAS  PubMed  Google Scholar 

Varvel S, McConnell JP, Tsimikas S. Prevalence of Elevated Lp(a) Mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239–45.

Article  CAS  PubMed  Google Scholar 

Tsimikas S. A test in Context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711.

Article  CAS  PubMed  Google Scholar 

Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–9.

Article  CAS  PubMed  Google Scholar 

Borrelli MJ, Youssef A, Boffa MB, Koschinsky ML. New frontiers in Lp(a)-Targeted therapies. Trends Pharmacol Sci. 2019;40(3):212–25.

Article  CAS  PubMed  Google Scholar 

Becker L, Nesheim ME, Koschinsky ML. Catalysis of covalent lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry. 2006;45(32):9919–28.

Article  CAS  PubMed  Google Scholar 

Force UPST. Statin use for the primary Prevention of Cardiovascular Disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746–53.

Article  Google Scholar 

Banach M, Penson PE, Statins. Secondary Prevention—So much progress, so far to go. JAMA Netw Open. 2020;3(11):e2025675–e.

Article  PubMed  Google Scholar 

Croyal M, Ouguerram K, Passard M, Ferchaud-Roucher V, Chétiveaux M, Billon-Crossouard S, et al. Effects of extended-release Nicotinic Acid on Apolipoprotein (a) kinetics in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol. 2015;35(9):2042–7.

Article  CAS  PubMed  Google Scholar 

Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.

Article  PubMed  Google Scholar 

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med. 2015;372(25):2387–97.

Article  CAS  PubMed  Google Scholar 

Sahebkar A, Simental-Mendía LE, Pirro M, Banach M, Watts GF, Sirtori C, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(1):17887.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–22.

Article  CAS  PubMed  Google Scholar 

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097–107.

Article  CAS  PubMed  Google Scholar 

O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483–92.

Article  PubMed  Google Scholar 

Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk after Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75(2):133–44.

Article  CAS  PubMed  Google Scholar 

Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 Heart Disease and Stroke statistics: a report of US and Global Data from the American Heart Association. Circulation. 2024;149(8):e347–913.

Article  PubMed  Google Scholar 

Blaha MJ, Bhatia HS. Lipoprotein(a), residual Cardiovascular Risk, and the search for targeted therapy. J Am Coll Cardiol. 2024;83(16):1540–2.

Article  CAS  PubMed  Google Scholar 

Birger M, Kaldjian AS, Roth GA, Moran AE, Dieleman JL, Bellows BK. Spending on Cardiovascular Disease and Cardiovascular Risk factors in the United States: 1996 to 2016. Circulation. 2021;144(4):271–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society Guidelines for the management of Dyslipidemia for the Prevention of Cardiovascular Disease in adults. Can J Cardiol. 2021;37(8):1129–50.

Article  PubMed  Google Scholar 

Koschinsky ML, Soffer DE, Boffa MB. What’s Next for Lipoprotein(a)? A National Lipid Association Report from an Expert Panel Discussion. Journal of Clinical Lipidology.

Afshar M, Kamstrup PR, Williams K, Sniderman AD, Nordestgaard BG, Thanassoulis G. Estimating the Population Impact of Lp(a) lowering on the incidence of myocardial infarction and aortic stenosis-brief report. Arterioscler Thromb Vasc Biol. 2016;36(12):2421–3.

Article  CAS  PubMed  Google Scholar 

Levin MG, Burgess S. Mendelian randomization as a Tool for Cardiovascular Research: a review. JAMA Cardiol. 2024;9(1):79–89.

Article  PubMed  Google Scholar 

Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470–7.

Article  CAS  PubMed  Google Scholar 

Emdin CA, Khera AV, Natarajan P, Klarin D, Won HH, Peloso GM, et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol. 2016;68(25):2761–72.

Article  CAS